AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
24 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
23 Mar 2020 04:40 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
23 Mar 2020 12:08 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 12:03 PM
RNS
Price Monitoring Extension
20 Mar 2020 10:20 AM
RNS
Second Price Monitoring Extn
20 Mar 2020 10:15 AM
RNS
Price Monitoring Extension
20 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Mar 2020 07:00 AM
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 07:00 AM
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 04:35 PM
RNS
Price Monitoring Extension
12 Mar 2020 11:00 AM
RNS
Notice of AGM
12 Mar 2020 07:00 AM
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2020 07:00 AM
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 07:00 AM
RNS
Filing of Form 20-F with SEC
03 Mar 2020 11:00 AM
RNS
Annual Financial Report
02 Mar 2020 03:00 PM
RNS
Total Voting Rights
02 Mar 2020 07:00 AM
RNS
Divestment of hypertension medicines completed
27 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
25 Feb 2020 07:00 AM
RNS
AstraZeneca divests global rights to Movantik
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2020 07:00 AM
RNS
AZN: Full-year and Q4 2019 results
03 Feb 2020 03:00 PM
RNS
Total Voting Rights
27 Jan 2020 07:00 AM
RNS
Enhertu Phase II trial met primary endpoint
27 Jan 2020 07:00 AM
RNS
Brilinta met primary endpoint in stroke trial
27 Jan 2020 07:00 AM
RNS
AstraZeneca divests hypertension medicines
27 Jan 2020 07:00 AM
RNS
AstraZeneca to recover brazikumab (MEDI2070)
20 Jan 2020 07:00 AM
RNS
FDA grants Lynparza Priority Review for PROfound
20 Jan 2020 07:00 AM
RNS
Imfinzi, tremelimumab granted ODD in liver cancer
13 Jan 2020 07:01 AM
RNS
Lynparza granted FDA Priority Review for PAOLA-1
13 Jan 2020 07:00 AM
RNS
Update on Epanova Phase III STRENGTH trial
06 Jan 2020 07:01 AM
RNS
Farxiga granted FDA heart failure Priority Review
06 Jan 2020 07:00 AM
RNS
Lokelma approved in China for hyperkalaemia
02 Jan 2020 03:00 PM
RNS
Total Voting Rights
30 Dec 2019 07:00 AM
RNS
US FDA approved Lynparza for pancreatic cancer
23 Dec 2019 07:00 AM
RNS
Triple-combination approved in China for COPD
23 Dec 2019 07:00 AM
RNS
Enhertu (trastuzumab deruxtecan) approved in US
20 Dec 2019 07:00 AM
RNS
AstraZeneca divests rights to Arimidex and Casodex
17 Dec 2019 06:06 PM
RNS
FDA panel backs Lynparza use for pancreatic cancer
16 Dec 2019 07:00 AM
RNS
Seroquel rights agreement complete: Europe, Russia
12 Dec 2019 07:00 AM
RNS
Imfinzi approved in China for Stage III NSCLC
11 Dec 2019 01:00 PM
RNS
Trastuzumab deruxtecan achieves ORR of 60.9%
05 Dec 2019 07:00 AM
RNS
Lynparza approved in China for 1L BRCAm ovarian
03 Dec 2019 07:00 AM
RNS
AstraZeneca divests Seroquel rights: US and Canada
02 Dec 2019 03:00 PM
RNS
Total Voting Rights
02 Dec 2019 03:00 PM
RNS
Block listing Interim Review
29 Nov 2019 07:00 AM
RNS
Imfinzi granted FDA Priority Review for SCLC
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings